{
    "clinical_study": {
        "@rank": "18433", 
        "acronym": "Himalayas", 
        "arm_group": [
            {
                "arm_group_label": "FG-4592 (Roxadustat)", 
                "arm_group_type": "Experimental", 
                "description": "FG-4592 (Roxadustat) will be dosed orally three times a week. The initial dose is based on weight. Thereafter, dosages will be adjusted based on Hb values and rate of change compared to previous Hb values."
            }, 
            {
                "arm_group_label": "Epoetin alfa", 
                "arm_group_type": "Active Comparator", 
                "description": "Epoetin alfa will be dispensed per the package insert or the country-specific product labeling."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether FG-4592 is safe and effective in the\n      treatment of anemia in patients who have just begun dialysis treatment for end stage renal\n      disease."
        }, 
        "brief_title": "Safety and Efficacy Study for Treatment of Anemia in Newly Initiated Dialysis Patients", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Anemia of End-stage Renal Disease", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Kidney Diseases", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "There is a screening period of up to 6 weeks, a treatment period of a minimum of 52 weeks\n      and a maximum of approximately 3 years after last patient is randomized, and a\n      post-treatment follow-up period of 4 weeks. A total of up to 750 patients will be randomized\n      in a 1:1 ratio to receive either open-label FG-4592 or Active Control (Epoetin alfa)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Receiving hemodialysis or peritoneal dialysis for end-stage renal disease for a\n             minimum of 2 weeks and a maximum of 4 months prior to study participation.\n\n          -  Study participant has permanent hemodialysis access in place.\n\n          -  No iron deficiency.\n\n          -  Blood tests will be conducted to determine whether or not study participant has\n             anemia, and causes of anemia.\n\n          -  No liver disease.\n\n          -  Body weight 45 to 160 kg (dry weight).\n\n        Exclusion Criteria:\n\n          -  Any erythropoiesis-stimulating agent treatment within 12 weeks prior to participating\n             in the study.\n\n          -  More than one dose of intravenous iron within 4 weeks prior to participating in the\n             study.\n\n          -  Red blood cell transfusion within 8 weeks prior to participating in the study.\n\n          -  Active infection.\n\n          -  Congestive heart failure.\n\n          -  Heart attack, stroke, or blood-clots within 12 weeks prior to participating in the\n             study.\n\n          -  Uncontrolled hypertension within 2 weeks prior to participating in the study.\n\n          -  Renal ultrasound performed within 12 weeks prior to participating in the study\n             suspicious of renal cancer.\n\n          -  Active cancer.\n\n          -  Positive for human immunodeficiency virus (HIV); hepatitis B or hepatitis C.\n\n          -  Chronic inflammatory disease that could cause anemia.\n\n          -  Known and untreated damage to the retina from diabetes.\n\n          -  Known history of blood-related diseases causing anemia, or blood-related cancer.\n\n          -  Known inherited disease such as thalassemia or sickle cell anemia or other known\n             causes for anemia other than chronic kidney disease.\n\n          -  Known clotting disorders and iron storage disorders.\n\n          -  Any prior organ transplant (that has not been explanted) or scheduled organ\n             transplantation.\n\n          -  Anticipated surgery that is expected to cause blood loss.\n\n          -  Known gastrointestinal bleeding.\n\n          -  Any prior treatment with FG-4592 or a hypoxia-inducible factor prolyl hydroxylase\n             inhibitor.\n\n          -  Use of iron-binding medications within 4 weeks prior to participating in the study.\n\n          -  Known allergies to any erythropoiesis-stimulating agent.\n\n          -  Use of an investigational drug or treatment, participation in an investigational\n             study, or presence of an expected carryover effect of an investigational treatment\n             within 4 weeks prior to participating in the study.\n\n          -  Anticipated use of dapsone in any dose amount or chronic use of acetaminophen or\n             paracetomol greater than 2.0 g/day during the treatment of follow-up periods of the\n             study.\n\n          -  History of alcohol or drug abuse within 2 years prior to participating in the study.\n\n          -  Women who can become pregnant must use contraception. Men with sexual partners who\n             can become pregnant must use birth control unless the man agrees to contraception.\n\n          -  Pregnant or breast-feeding women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "750", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02052310", 
            "org_study_id": "FGCL-4592-063", 
            "secondary_id": "2013-002753-30"
        }, 
        "intervention": [
            {
                "arm_group_label": "FG-4592 (Roxadustat)", 
                "intervention_name": "FG-4592", 
                "intervention_type": "Drug", 
                "other_name": "Roxadustat"
            }, 
            {
                "arm_group_label": "Epoetin alfa", 
                "intervention_name": "Epoetin Alfa", 
                "intervention_type": "Drug", 
                "other_name": "Procrit, Epogen"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Epoetin Alfa"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Anemia", 
            "Chronic Kidney Disease", 
            "hemoglobin", 
            "End-Stage Renal Disease", 
            "Incident-Dialysis", 
            "Erythropoetin", 
            "Erythropoeisis stimulating-agent", 
            "ASP1517"
        ], 
        "lastchanged_date": "April 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Dobrich", 
                        "country": "Bulgaria", 
                        "zip": "9300"
                    }, 
                    "name": "Investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pazardjik", 
                        "country": "Bulgaria", 
                        "zip": "4400"
                    }, 
                    "name": "Investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pernik", 
                        "country": "Bulgaria", 
                        "zip": "2300"
                    }, 
                    "name": "Investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ruse", 
                        "country": "Bulgaria", 
                        "zip": "7000"
                    }, 
                    "name": "Investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria", 
                        "zip": "1431"
                    }, 
                    "name": "Investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Goyang-Si", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do", 
                        "zip": "410-719"
                    }, 
                    "name": "Investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Krasnodar", 
                        "country": "Russian Federation", 
                        "zip": "350029"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Novorossiysk", 
                        "country": "Russian Federation", 
                        "zip": "353915"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omsk", 
                        "country": "Russian Federation", 
                        "zip": "644112"
                    }, 
                    "name": "Investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orenburg", 
                        "country": "Russian Federation", 
                        "zip": "460040"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "196247"
                    }, 
                    "name": "Investigational site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "197110"
                    }, 
                    "name": "Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Bulgaria", 
                "Korea, Republic of", 
                "Russian Federation"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 3, Multicenter, Randomized, Open-Label,Active-Controlled Study of the Efficacy and Safety of FG-4592 in the Treatment of Anemia in Incident-Dialysis Patients", 
        "overall_contact": {
            "email": "063study@fibrogen.com", 
            "last_name": "Clinical Trial Coordinator", 
            "phone": "415-978-1200", 
            "phone_ext": "1672"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Ukraine: State Pharmacological Center - Ministry of Health", 
                "Estonia: The State Agency of Medicine", 
                "Belarus: Ministry of Health", 
                "Bulgaria: Bulgarian Drug Agency", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Malaysia: Ministry of Health", 
                "Taiwan : Food and Drug Administration", 
                "Korea: Ministry of Food and Drug Safety", 
                "Hong Kong: Department of Health", 
                "Thailand: Food and Drug Administration", 
                "Romania: Ministry of Public Health", 
                "Latvia: State Agency of Medicines", 
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Chile: Ministry of Health", 
                "Mexico: Federal Commission for Protection Against Health Risks", 
                "Peru: General Directorate of Pharmaceuticals, Devices, and Drugs", 
                "Brazil: National Health Surveillance Agency", 
                "Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Cumulative number (%) of subjects with hemoglobin greater than or equal to 11g/dL and increase of greater than or equal to 1 g/dL from baseline up to 24 weeks.", 
            "measure": "Hemoglobin response to treatment using various FG-4592 dosing regimens.", 
            "safety_issue": "No", 
            "time_frame": "Change from Baseline hemoglobin to 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02052310"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Mean change in Hb averaged over 8 weeks of treatment at Weeks 28-36, without rescue therapy within 6 weeks prior to and during this 8 week evaluation period.", 
                "measure": "Hemoglobin maintenance once correction is achieved.", 
                "safety_issue": "No", 
                "time_frame": "Week 28-36"
            }, 
            {
                "description": "Average monthly IV iron use per subject", 
                "measure": "Average monthly IV iron use per subject", 
                "safety_issue": "No", 
                "time_frame": "Weeks 1 up to 156 weeks."
            }, 
            {
                "measure": "Mean change in low-density lipoprotein (LDL) cholesterol", 
                "safety_issue": "No", 
                "time_frame": "Weeks 12-24"
            }, 
            {
                "description": "At least one of the following criteria must be met in order to be considered an exacerbation of hypertension: an increase in anti-hypertensive medication use; an adverse event of hypertension or an increase in blood-pressure from baseline confirmed by repeat measurement.", 
                "measure": "Cumulative number (%) of patients with with exacerbation of hypertension.", 
                "safety_issue": "Yes", 
                "time_frame": "Change in blood pressure from baseline up to weeks 156."
            }, 
            {
                "description": "Time to achieve first Hb response as defined by the primary endpoint.", 
                "measure": "Time to achieve Hemoglobin response", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks"
            }, 
            {
                "description": "Health-related quality of life (HRQoL) will be assessed using the SF-36, vitality and physical functioning subscales. Both within-treatment and between-treatment effect will be assessed.", 
                "measure": "Change in the Health-related quality of life (HRQoL)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 12, 28 and 52."
            }
        ], 
        "source": "FibroGen", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Astellas Pharma Europe B.V.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "AstraZeneca", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "FibroGen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}